THE GLOBAL CANNABIS INDUSTRY WILL GRADUALLY OPEN UP OVER THE NEXT THREE YEARS TO BECOME ONE OF THE FASTEST GROWING MARKETS IN THE WORLD.
We provide market intelligence and strategic consultancy to investors, entrepreneurs and regulators who are ready to embrace opportunity in this emerging frontier.
Our reliable and credible insight is maturing the conversation and opening up the market.
MArket Data & Insights
Ongoing free reports and content including The European Cannabis Report™ and European Cannabis Weekly newsletter.
Detailed research and analysis for both regulators and investors interested in the potential of the European market.
Market entry and expansion strategy including regulatory relationships, licensing applications and cross border commerce.
Prohibition Partners is delighted to announce the launch of The European Country Panel, an online community of thought leaders in the European cannabis industry. This panel brings together selected members of the industry, representing over 28 countries, to share information, discuss ideas and develop new opportunities. If you are interested in joining the European Country Panel, please contact our Community Manager, Olivia Rutter, at firstname.lastname@example.org.
Canadian cannabis companies look to European funds, Aurora acquires the largest hemp producer on the continent and Tilray exports cannabis oils to a paediatric patient in the UK. In France, the Medicines Agency will evaluate the country’s medical cannabis system in late September.
Aphria secures a Danish partner to produce organic medical cannabis, MGC signs European distribution deals and Pure Global Cannabis lists on the German Stock Exchange. Elsewhere, Canopy stock surges and research shows big pharma hold the majority of cannabis patents.
Maricann and San Martino plan to enter into cannabis joint venture in Italy, while Danish cultivator Danavian Cannabis Ltd. is acquired by Kaneh Bosm. Meanwhile, Germany calls for help from the Netherlands to meet the country’s soaring medical cannabis demand.
The Green Organic Dutchman acquires Polish CBD company HemPoland for €30 million, while British beverage giant Diageo explores investment options in the cannabis space. Meanwhile European Parliament prepares a motion for a resolution on medical cannabis, and a New study examines the role cannabis plays in treating Parkinson's and Alzheimer's.
Maricann completes first shipment of cannabis flower into Germany, while elsewhere Aurora ships mother plants into Denmark to begin cultivation for Aurora Nordic. Meanwhile, the UN begins its first formal review into cannabis scheduling in international law, and dispensary chain MedMen launch a €3.5 million ad campaign.
Cannabis companies raise over €6.9 billion in 2018, MedMen list on the Frankfurt Stock Exchange and Epidiolex looks set to cost patients €28,000 per year in the US. Meanwhile, UK politicians push for reform and LP’s look to make moves in South America.
CROP set to harvest 600,000 plants of ‘cannabis light’ in Autumn. Canadian companies are tapping into the Swiss market as Italy’s health minister pushes for private cultivation licences. Meanwhile, Israeli exports stall and Molson Coors creates a cannabis joint venture.
Germany is experiencing a ‘blistering’ rate of growth as Together signs a €10 million export deal. In a historic development, UK doctors will be able to prescribe medical cannabis by Autumn 2018 and Swiss politicians for cannabis pilot projects. Meanwhile, we have launched the European Country Panel, connecting Europe’s most influential players in the European cannabis industry.
The German government has announced that they are going to re-start their cannabis cultivation tender as the UK’s Advisory Council the Misuse of Drugs recommends rescheduling some cannabis-based medicines. Prohibition Partners’ European Cannabis Report™ predicts that Europe's legal cannabis market will be worth €115 billion within 10 years.
MGC Pharmaceuticals secure a European cannabis manufacturing license for a facility in Slovenia, whilst elsewhere, XHemplar plant up 25 acres of ‘cannabis light’ in Italy. Meanwhile, Genetically modified cannabis may be close to a breakthrough, and Prohibition Partners announce the release of The European Cannabis Report™ 3rd Edition.
By 2028, the European cannabis market will be worth €115.7 billion, according to market intelligence and strategic consultancy firm, Prohibition Partners. The findings come from The 3rd Edition of The European Cannabis Report™, a new report calculating the potential value of a fully legal cannabis market across 28 key countries in Europe.
Since March 2017, medical cannabis has been legal in Germany, launching a new domestic industry, and attracting the watchful eye of the global cannabis community.
Previously, the state had only accepted applications from around 1,000 patients who had navigated rigorous regulations in order to legally access cannabis treatments. However, as of March 2018, the number of applications to the health insurance companies has risen to 13,000, with over 60% of requests for reimbursement being approved.
Dutch cannabis laws are not without fault. Since the introduction of coffee shops in 1976, Amsterdam’s cannabis has been supplied by criminal organisations. Additionally, a lack of cannabis cultivation licences, since 2003, has allowed Bedrocan to develop a monopoly. But as the global reform on cannabis begins, the Netherlands are experimenting with cultivation licences in a bid to grow the industry.
France is emblematic of the hypocritical cannabis policies exhibited in Western Europe. More people consume cannabis in France than anywhere else in Europe, but despite recent amendments to the 1970 cannabis law, France is still missing out on a hugely profitable market.
Starting in the 1960s, Finland, like its Scandinavian neighbours developed a history of drug prohibition. However, Finland is too often tarred with the same brush as Sweden’s repressive policies. In reality, since 2008, Finland has legalised medical cannabis and reformed the formerly punitive cannabis policies. Although mainstream politics avoids the subject of full legalisation, youth parties are fighting for reform in the happiest country in the world.
In Sweden medical cannabis use has been considered an aggravating circumstance rather than an extenuating circumstance as many patients have suffered at the hands of punitive state laws. However, as two historic cannabis licences have been granted, Sweden may no longer be able to remain an island in the changing global consensus on cannabis.
On the whole, public policies in the Nordic countries are usually informed by modern science and human rights. Drug policy is, arguably, the notable exception. Current cannabis laws in Norway are not based on any real science of humanism but largely as a result of the fearmongering rhetoric of the 60s and 80s. However, as much of Europe rolls back the embargo on medical cannabis, Norway is looking to differentiate itself from the typically repressive Scandinavian cannabis policies.
Estonia is starkly juxtaposed with the rest of Europe in the medical cannabis space. On one side, the state are surprisingly keen to implement some form of medical cannabis system but on the other, caution and anxiety pervade mainstream public opinion on cannabis reform.